What Happened

A 30-year-old licensed pharmacist from Pittsfield, Massachusetts pleaded guilty in federal court in Boston on September 17, 2026, to five counts of acquiring a controlled substance by fraud, deception and subterfuge.

According to the U.S. Attorney's Office for the District of Massachusetts, the defendant admitted that while working as a licensed pharmacist at a national pharmacy chain, he diverted dextroamphetamine — described in the plea as generic Adderall — for his own use on four separate occasions in August, September and November 2024. On November 10, 2024, he also diverted Adderall. All of the controlled substances he took were originally intended for the pharmacy's customers.

The defendant was charged in July 2026 and entered his guilty plea two months later, in September 2026. U.S. Senior District Judge William G. Young scheduled sentencing for December 15, 2026; no sentence has yet been imposed. The offense carries a statutory maximum of up to four years in prison, one year of supervised release and a $250,000 fine.

The case was investigated by the DEA's New England Field Division, with assistance from the Massachusetts State Police, the Barnstable County Sheriff's Department, and the Barnstable, Harwich, Bourne, Brewster, Sandwich, Falmouth, Mashpee, Yarmouth and Dennis police departments. Assistant U.S. Attorney Meghan Cleary of the Health Care Fraud Unit is prosecuting the case.

What Went Wrong

The guilty plea confirms a pattern that pharmacy diversion programs are specifically designed to catch early:

  • Diversion continued across multiple months. The admitted conduct spans four separate occasions from August through November 2024 — a repeated pattern rather than a single lapse, which is typical of diversion that goes undetected for a period before it surfaces.
  • The pharmacist used legitimate professional access. As a licensed pharmacist, the defendant had authorized access to the controlled substances he diverted. The charge — acquiring a controlled substance by fraud, deception and subterfuge — is the standard federal charge for insiders who misuse legitimate access rather than break in from outside.
  • The diverted drugs were meant for patients, not the pharmacist. Every dose taken was originally intended for a customer of the pharmacy, meaning each diversion event also represented a disruption to a patient's prescribed treatment.
  • It took a multi-agency federal investigation to build the case. DEA, state police and multiple local police departments were all involved, underscoring how much investigative effort is typically required to substantiate pharmacist-level diversion after the fact.

How It Could Have Been Prevented

Cases like this one illustrate why pharmacy operators build layered controls around pharmacist access to controlled substances rather than relying on trust alone:

  • Reconcile dispensing records against prescriptions filled on a regular basis, so quantities removed without a matching, valid prescription are flagged quickly rather than accumulating over months.
  • Use automated medication dispensing and monitoring systems that log every access event by user, so unusual withdrawal patterns by any single pharmacist — including the pharmacist responsible for oversight — can be reviewed independently.
  • Require a second-person check or periodic audit of high-diversion-risk stimulants like Adderall and its generics, since these drugs are frequent diversion targets in retail pharmacy settings.
  • Route any discrepancy between dispensed quantities and verified patient pickups through a documented investigation process, rather than allowing repeated small gaps to go unexplained.
  • Remember that pharmacist-level access does not exempt anyone from diversion controls — the people with the most access to controlled substances need the most consistent oversight, not the least.

Related Guidance

Sources